Metabolic Determinants of Cardiovascular Dysfunction in Obesity

描述(申请人提供)：心血管疾病继发的发病率和死亡率是肥胖患者的主要健康问题。肥胖患者背负着一系列与超重相关的代谢功能障碍。其中最值得注意的是胰岛素抵抗，它会导致血浆化学的有害变化，胰岛素的代偿性过度生产，并最终导致胰岛β细胞衰竭和2型糖尿病。由于肥胖患者同时存在代谢和心血管功能障碍，因此人们普遍怀疑这两个变量是因变量。这在多大程度上是真实的，以及代谢和心血管疾病之间的联系机制尚不清楚。在这一应用的初步数据中，我们建立了一种新的小鼠模型，在该模型中，肥胖小鼠的胰岛素受体脱敏基因蛋白酪氨酸磷酸酶1B(PTP1B)被缺失。结果是一只持续肥胖并纠正了外周胰岛素抵抗的小鼠。肥胖小鼠在体外表现出微血管内皮细胞NO介导的血管扩张功能受损，这一缺陷通过PTP1B缺失得到纠正。这表明胰岛素抵抗是肥胖引起的代谢功能障碍的原因。目标1将确定这些微血管缺陷背后的分子机制。目标2将以血流、血压和血管重塑为终点，确定纠正肥胖小鼠胰岛素抵抗对心血管的影响。虽然初步数据提供了新的证据，表明胰岛素抵抗和心血管功能障碍之间存在联系，但这种关系的性质尚不清楚。肥胖小鼠体内高水平的HbA1c表明存在有利于非酶糖化的环境，这种联系因晚期糖基化终末产物受体(RAGE)表达的增加而得到加强。在肥胖的PTP1B基因缺失小鼠中，这两种缺陷都得到了纠正，但胰岛素抵抗有所改善。这就引出了这样一种假设，即RAGE是胰岛素抵抗和心血管功能障碍之间的机械联系，这一假设将在目标3中通过产生新型的双重KO小鼠来检验，即缺乏RAGE的肥胖小鼠。综上所述，这些研究将产生关于肥胖引起的代谢功能障碍的机制、介体和生理影响的新信息。成功完成这些目标可能会确定新的靶点，以帮助治疗肥胖症最常见的临床结果。

DESCRIPTION (provided by applicant): Morbidity and mortality secondary to cardiovascular disease is the major health problem in obese patients. Obese patients are burdened with an array of metabolic dysfunctions associated with excess weight. Most notable of these is insulin resistance which causes deleterious changes in plasma chemistry, compensatory over-production of insulin and eventual failure of the pancreatic beta-cell and Type 2 diabetes. Because obese patients present with both metabolic and cardiovascular dysfunction, it is widely suspected that the two are dependent variables. The extent to which this is true and the mechanisms linking metabolic and cardiovascular disease are unknown. In preliminary data for this application, we have generated a novel mouse model in which an insulin receptor desensitizing gene, protein tyrosine phosphatase 1B (PTP1B) is deleted from obese mice. The result is a mouse with persistent obesity and correction of peripheral insulin resistance. Obese mice show impairment of microvascular endothelial NO-mediated vasodilation in vitro, a defect corrected by PTP1B deletion. This suggests that insulin resistance is the causal aspect of obesity-induced metabolic dysfunction. The molecular mechanisms underlying these microvascular defects will be determined in Aim 1. The cardiovascular impact of correcting insulin resistance in obese mice will be determined in Aim 2, using blood flow, blood pressure and vascular remodeling as endpoints. While preliminary data provides novel evidence that insulin resistance and cardiovascular dysfunction are linked, the nature of this relationship is unclear. High levels of HbA1c in obese mice suggest an environment favorable to non-enzymatic glycation and this association is strengthened by the increased expression of the Receptor for Advanced Glycation End-products (RAGE). Both deficits are corrected in obese PTP1B null mice with improved insulin resistance. This leads us to the hypothesis that RAGE is the mechanistic link between insulin resistance and cardiovascular dysfunction and this hypothesis will be tested in Aim 3 by the generation of novel dual KO mice, obese mice lacking RAGE. Taken together, these studies will generate new information about the mechanisms, mediators and physiologic impact of obesity-induced metabolic dysfunction. Successful completion of these aims may identify new targets to aid in the treatment of the most common clinical outcomes of obesity.